Oral apixaban for the treatment of acute venous thromboembolism.

@article{Agnelli2013OralAF,
  title={Oral apixaban for the treatment of acute venous thromboembolism.},
  author={Giancarlo Agnelli and Harry R. Buller and Alexander Cohen and Madelyn Curto and Alexander S. Gallus and Margot Johnson and Urszula Masiukiewicz and Raphael Pak and J. A. Thompson and Gary E. Raskob and Jeffrey I Weitz},
  journal={The New England journal of medicine},
  year={2013},
  volume={369 9},
  pages={799-808}
}
BACKGROUND Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or… CONTINUE READING
Highly Influential
This paper has highly influenced 44 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
449 Citations
12 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 449 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 12 references

Oral riva- roxaban for symptomatic venous thrombo- embolism

  • The EINSTEIN Investigators
  • N Engl J Med
  • 2010

Idrap- arinux versus standard therapy for venous thromboembolic disease

  • The van Gogh Investigators
  • N Engl J Med
  • 2007

Similar Papers

Loading similar papers…